Study of how lung bacteria spreads in people with cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of cystic fibrosis (CF).
- You meet CF diagnostic standards used by the Cystic Fibrosis Foundation (2017 guidelines).
- You have had nontuberculous mycobacteria (NTM) before, or your first positive NTM test came from routine care.
- Your first positive NTM test was taken from a lung sample such as expectorated sputum or induced sputum, a throat/oral swab, or a bronchoalveolar lavage.
- You can be any age and you can be male or female.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a urine test (instead of repeated sputum—mucus—from the lungs testing) can help determine who with cystic fibrosis does not have certain lung germs called NTM. If the urine test works, it could reduce the need for lung sample testing while still keeping people safe.
This study looks at how NTM bacteria spread among people. If you have had a positive NTM test from your lungs, you may be able to help by sharing a sample for research.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This study looks at how highly effective CF modulator therapies change the bacteria living in the lungs of people with cystic fibrosis. Understanding these changes may help improve future treatments.
This study looks at the community of tiny organisms in the lungs (the lung microbiome) in people with bronchiectasis caused by NTM (non-tuberculous mycobacteria). It compares people with positive NTM cultures to people without, to better understand what’s going on in the lungs and why symptoms may differ.
This study looks at whether people with cystic fibrosis (CF) can pick up nontuberculous mycobacteria (NTM) from their home environment. It compares homes of people with CF who have NTM to those who don't, to see where germs might be hiding.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.